Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Gross Margin (2016 - 2025)

Historic Gross Margin for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to 96.71%.

  • Ligand Pharmaceuticals' Gross Margin rose 14300.0% to 96.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 94.27%, marking a year-over-year increase of 7500.0%. This contributed to the annual value of 93.37% for FY2024, which is 13800.0% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Gross Margin stood at 96.71%, which was up 14300.0% from 93.9% recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Gross Margin registered a high of 96.71% during Q3 2025, and its lowest value of 57.1% during Q4 2022.
  • Its 5-year average for Gross Margin is 85.26%, with a median of 89.4% in 2023.
  • In the last 5 years, Ligand Pharmaceuticals' Gross Margin crashed by -216500bps in 2022 and then soared by 370600bps in 2023.
  • Ligand Pharmaceuticals' Gross Margin (Quarter) stood at 78.75% in 2021, then fell by -27bps to 57.1% in 2022, then skyrocketed by 65bps to 94.16% in 2023, then fell by -1bps to 93.37% in 2024, then increased by 4bps to 96.71% in 2025.
  • Its last three reported values are 96.71% in Q3 2025, 93.9% for Q2 2025, and 89.3% during Q1 2025.